As model‐informed drug development becomes an integral part of modern approaches to the discovery of new therapeutic entities and showing their safety and effectiveness, modalities of incorporating the paradigm into widespread practice require a revisit. Traditionally, modeling and simulation (M&S) have been performed by specialized teams who (…)
Author(s): Amin Rostami‐Hodjegan, Frederic Y. Bois
Year: 2021 年 4 月 1 日
